

**Recommendations from York and Scarborough Medicines Commissioning Committee October 2015**

Drug name	Indication	Recommendation	Rationale for recommendation	Place in therapy	RAG status	Potential full year cost impact
Alprostadil urethral sticks (MUSE®)	Erectile dysfunction	Approved for use as per Vale of York RSS guidance.	Refer to Vale of York RSS guidance.	Only for men who meet the criteria listed in part XVIII B of the Drug Tariff.	Green	No significant impact expected as currently prescribed.
Alprostadil intracavernous injection (Caverject®)	Erectile dysfunction	Approved for use as per Vale of York RSS guidance.	Refer to Vale of York RSS guidance.	Only for men who meet the criteria listed in part XVIII B of the Drug Tariff.	Green	No significant impact expected as currently prescribed.
Naltrexone/bupropion (8mg/90mg) tablets (Mysimba®)	Weight management	Not approved for use.	No costings information - Further longer term safety and efficacy data is required before Mysimba® can be recommended for use.	Not routinely commissioned	Black	Nil
Insulin degludec 100 units/mL / liraglutide 3.6 mg/mL (Xultophy®)	Adults with type 2 diabetes	Not approved for use.	Other than administration of a single daily injection, additional clinical benefit over using separate basal insulin and GLP-1 analogue agents has not been demonstrated.	Not routinely commissioned	Black	Nil
Edoxaban 15mg, 30mg and 60mg tablets (Lixiana®)	Stroke prevention and systemic embolism in people with non valvular atrial fibrillation	Approved.	An option as per NICE TA 355	An option to prevent stroke and systemic embolism in people with non-valvular AF who have one or more risk factors, such as:	Green	Costs similar to other NOACs approved by NICE.

				<ul style="list-style-type: none"> <li>• heart failure, high blood pressure or diabetes</li> <li>• had a stroke or transient ischaemic attack before</li> <li>• aged 75 years or older.</li> </ul>		
Ruxolitinib tablets (Jakavi®)	Polycythaemia vera	Not approved for use.	NICE terminated appraisal TA 356. No evidence submitted to NICE from Novartis Pharmaceuticals.	Not routinely commissioned	Black	Nil
Humalog 200 unit Kwikpen*	Diabetes mellitus requiring insulin	Approved.	Cost neutral.	Where a rapid acting insulin analogue is indicated. Refer to <a href="#">NICE</a> .	Green	No impact on cost.
Tiotropium 2.5microgram and olodaterol 2.5microgram inhalation solution (Spiolto® Respimat®)	COPD	Not approved for use.	Product launched after CCG COPD pathway published.	Not routinely commissioned, will be considered at next COPD pathway review.	Black	Nil
Saxenda® (liraglutide 3mg)**	Weight management	Not approved for use.	New product – any proposed usage will require an evidence submission to MCC.	Not routinely commissioned	Black	Nil

\* Humalog KwikPen is available in two strengths. For both, the dose is dialled in units. Both pre-filled pens, the Humalog 100 units/ml KwikPen and the Humalog 200 units/ml KwikPen deliver 1 – 60 units in steps of 1 unit in a single injection. The dose counter shows the number of units regardless of strength.

\*\* Saxenda® is a new product containing liraglutide licensed for weight management. This product should not be confused with liraglutide 6 mg/mL solution for injection in pre-filled pen (Victoza®) which is only licensed for treatment of type 2 diabetes.

#### Other items

- Palliative care formulary